Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 4/20 | 0.40 |
| ▸ | LPL | P06858 | 11/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21176481 | 0.81 | ESR1 (0.46) | ESR1 | |
| SCHEMBL25065899 | 0.77 | LPL (0.51) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL428848 | 0.69 | CA1 (0.56) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL1767732 | 0.67 | LPL (0.56) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL22748749 | 0.66 | LPL (0.48) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL15064540 | 0.65 | CA1 (0.51) | SNCALPLLIPGDGAT1CA1 | |
| SCHEMBL16790069 | 0.64 | LPL (0.56) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL5243207 | 0.64 | CA1 (0.61) | SNCALPLLIPGDGAT1CA1 | |
| SCHEMBL2439887 | 0.64 | LIPG (0.41) | SNCAESR1LPLLIPGHIF1A | |
| SCHEMBL17690775 | 0.63 | CA1 (0.47) | SNCALPLLIPGDGAT1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360543-A1 | RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER | UNIV ILLINOIS (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200360543-A1 | RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER | UNIV ILLINOIS (US) | 2020-11-19 | — | — | US | disclosed |
| US-20190224346-A1 | RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
| US-20190224346-A1 | RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224346-A1 | RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER | ESRRG, ESR1, ESR2 | SNCA 4790/4885ESR1 2/4885LPL 1046/4885 |
| US-20200360543-A1 | RADIOTRACERS FOR IMAGING ER-POSITIVE BREAST CANCER | ESRRG, ESR1, ESR2 | SNCA 4790/4885ESR1 2/4885LPL 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.